Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025
Reuters
Oct 15
<a href="https://laohu8.com/S/TEM">Tempus AI</a> Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025
Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.